Ardigen and ImmuMap announce a research partnership for T-cell receptor discovery
Today, Ardigen, a leading AI and bioinformatics partner for drug developers, and ImmuMap, a state-of-the-art flow cytometry CRO, announce a research partnership. Ardigen has obtained a grant from the EU-based European Regional Development Fund under the Intelligent Development Program and partnered for the selected experimental work.
The scope of the collaboration between ImmuMap and Ardigen will revolve around the identification of T-cell receptors reactive towards newly identified neoantigens of solid tumor patients. Applied experimental methods will include ELISpot, NGS sequencing, MHC multimers staining and sorting as well as 10x Genomics single cell immune profiling. The data collected with the above experiments will validate Ardigen’s AI technology and further feed its development according to the principle of positive feedback-loop between laboratory experiments and artificial intelligence. The project will expand Ardigen’s capabilities of accelerating the TCR-based therapy discovery and development.
“We are really excited to partner with Ardigen on this study applying our expertise within antigen-specific T cell detection and profiling. Ardigen’s massive efforts to build AI in this field has the potential to accelerate clinical development and ultimately secure faster and better treatment of life-threatening disease. We are proud and humble to be part of this”, says Thomas Mørch Frøsig, CEO of ImmuMap.
About Immumap Services ApS
ImmuMap offers bespoke solutions within cellular immunity analysis based on flow cytometry assays and enzyme- or fluorescence-linked immunospot (ELISpot/fluorospot) for immune monitoring and consulting. Staffed by PhD-level scientists and co-founded by immune technology key opinion leader Dr. Sine Reker Hadrup, ImmuMap’s business has extensive scientific and methodological expertise at its core, which allows ImmuMap to be the perfect partner for its customers.
ImmuMap have developed several platforms for high-throughput screening and profiling of antigen-specific T cells, including the Deep Profiling assay, providing multilayered characterization of specific T cell populations, and the dCODE™ platform, used for parallel identification and enumeration of 50–1183 different T cell specificities.
The project is co-financed by the European Union from the European Regional Development Fund under the Intelligent Development Program. The project won funding in the call of the National Center for Research and Development: Quick Path.”